UAE Pharmaceutical Company License Guide 2026: Import, Distribute or Manufacture Drugs & Medical Devices in UAE

Updated August 2026. The UAE pharmaceutical sector is one of the most tightly regulated commercial activities in the country — and one of the most valuable. With a market exceeding AED 20 billion and annual growth of 12%, the UAE serves as the GCC’s primary pharmaceutical hub. Over 95% of all drugs sold here are imported, creating substantial opportunity for international manufacturers, distributors, and medical device companies. However, the licensing framework is multi-layered: it involves federal health authorities, emirate-level departments, and mandatory product-by-product registration that many first-time entrants underestimate. This guide covers every license type, cost component, and regulatory step for companies seeking to import, distribute, manufacture, or retail pharmaceutical products and medical devices in the UAE in 2026.

Who Regulates Pharmaceuticals in the UAE?

The UAE operates a dual-track regulatory system: a federal authority sets national standards and oversees product registration, while each emirate’s health department licenses establishments within its borders. Understanding which authority governs each approval is essential before beginning any application.

Types of Pharmaceutical Companies and Licenses Required

The license pathway depends entirely on the company’s activity. Importing, manufacturing, retailing, and brand representation each carry a distinct regulatory route. Operating outside the scope of your license — for example, distributing drugs under a trade-only license — is a serious regulatory violation in the UAE.

MOHAP Pharmaceutical Establishment License

The MOHAP pharmaceutical establishment license is the foundational federal approval that authorises a company to commercially import, distribute, or deal in pharmaceutical products anywhere in the UAE. It is separate from — and required in addition to — the DED commercial trade license. Without this license, no pharmaceutical product can legally clear UAE customs for commercial sale, and no hospital or pharmacy is permitted to purchase from the company.

• Who requires it: Any company commercially handling pharmaceutical products — importers, distributors, wholesalers, and re-exporters operating on the mainland
• Application portal: MOHAP digital services portal (mohap.gov.ae)
• Processing timeline: 3–6 months for first-time applicants; supporting documents include company incorporation papers, warehouse details, and named pharmacist
• Annual renewal: Required; a lapsed establishment license immediately suspends import and distribution rights
• Mandatory staff requirement: A UAE-licensed pharmacist must be named as the responsible officer on the establishment license at time of application

Pharmaceutical Product Registration: The Step Most Companies Underestimate

Obtaining the establishment license does not permit importing any specific drug. Every pharmaceutical product must be individually registered with MOHAP before a single unit can enter the UAE commercially. This product-by-product requirement is the most time-consuming and cost-intensive aspect of setting up a pharmaceutical business in the UAE — and the step that consistently catches new market entrants off-guard.

Strategic planning note: Companies entering the UAE pharma market should submit product registration applications at least 12–18 months before their planned commercial launch. For a portfolio of 10 products, registration fees alone reach AED 50,000–250,000 before a single sale is made. Staggering submissions — prioritising highest-revenue products first — is standard practice for established international pharma companies entering the market.

Cost Breakdown: UAE Pharmaceutical Import and Distribution Company (Year 1)

The following cost model covers a Year 1 mainland pharmaceutical importer and distributor operating with a portfolio of five registered products and a GDP-compliant warehouse.

Excludes product inventory, import duties, marketing spend, and additional staff beyond the mandatory pharmacist.

Free Zone Pharmaceutical Licensing: JAFZA, Dubai South, and KIZAD

UAE free zones offer 100% foreign ownership, streamlined setup, and competitive logistics infrastructure — but pharmaceutical companies must understand a hard operational boundary before choosing a free zone structure.

The critical rule: A free zone pharmaceutical license permits import, storage, and re-export to GCC or international markets only. Supplying UAE-based hospitals, clinics, or pharmacies requires a mainland entity with a valid MOHAP pharmaceutical establishment license. Many international pharmaceutical companies operate a dual structure: the free zone entity manages logistics and handles re-export to regional markets; a separate mainland entity holds the establishment license for UAE domestic distribution.

Medical Device Registration in UAE: A Separate Pathway from Drug Registration

Medical devices are regulated separately from pharmaceuticals, with ESMA’s classification framework determining the approval route, documentation requirements, and timeline. Companies dealing in both pharmaceuticals and medical devices must maintain parallel registration tracks — there is no combined pathway.

GMP Requirements for Pharmaceutical Manufacturers

Companies seeking to manufacture pharmaceutical products inside the UAE face the most stringent licensing pathway. UAE GMP standards are based on WHO GMP guidelines and require a formal MOH inspection before any manufacturing license is issued.

• GMP inspection by MOH: Conducted before the manufacturing license is granted; covers facility layout, equipment qualification, environmental controls, documentation systems, and quality management infrastructure
• Annual audit: Ongoing GMP compliance is monitored; a failed audit leads to license suspension and must be remediated before operations can resume
• Full pathway: DED industrial license + MOHAP manufacturing license + successful GMP inspection + individual product registration for each item manufactured
• Market context: Very few pharmaceutical manufacturing facilities currently operate in UAE; the sector remains overwhelmingly import-dependent; KIZAD in Abu Dhabi is the primary designated zone for new manufacturing investment
• Government incentive: The UAE Industrial Strategy 2031 actively targets pharmaceutical manufacturing growth; incentive packages including subsidised land and utilities are available for qualifying manufacturing investors

Frequently Asked Questions

How long does pharmaceutical product registration take in the UAE?

Product registration with MOHAP takes 6 to 24 months per product, depending on drug category, completeness of the submission dossier, and whether the product qualifies for expedited review. Fast-track pathways are available for WHO pre-qualified products and for drugs already holding registration in GCC countries such as Saudi Arabia (SFDA) or Kuwait — even with fast-track, a minimum of 3–6 months should be budgeted. The critical planning implication: pharmaceutical companies entering the UAE market should submit product registration applications at least 12–18 months before their planned commercial launch date. Registering multiple products simultaneously does not compress individual timelines — each product is reviewed and approved independently by MOHAP.

Can a free zone pharmaceutical company supply drugs to UAE hospitals and pharmacies?

No. A pharmaceutical company licensed solely within a UAE free zone — including JAFZA, Dubai South, or any other free zone — cannot sell or distribute pharmaceutical products to UAE mainland customers such as hospitals, clinics, or retail pharmacies. Free zone pharmaceutical licenses are limited to import, storage, and re-export to GCC or international markets. To supply the UAE domestic healthcare market, the company must establish a mainland entity, obtain a DED commercial license with pharmaceutical distribution activity, and secure a MOHAP pharmaceutical establishment license. The dual-entity structure is common among international pharmaceutical companies: the free zone entity manages regional logistics and re-export; the mainland entity holds the establishment license for UAE domestic distribution contracts.

Is a qualified pharmacist mandatory for a pharmaceutical distribution company in UAE?

Yes — it is a non-negotiable legal requirement under MOHAP regulations. Any company holding a pharmaceutical establishment license must employ a UAE-licensed pharmacist as the named responsible officer for all pharmaceutical activities. This requirement applies at the point of license application; a company cannot obtain its establishment license without a qualified pharmacist already on staff and named in the submission. The pharmacist must hold a UAE MOH professional license, which requires degree verification, passing a professional licensing examination, and registration with the relevant emirate health authority. Salary benchmarks range from AED 120,000 to AED 250,000 per year depending on experience and specialisation — typically the largest recurring human resources cost for a pharmaceutical distribution business in its early years.

What is the difference between medical device registration and drug registration in UAE?

The two pathways differ in the regulatory bodies involved, classification frameworks, documentation requirements, and timelines. Pharmaceutical drugs are registered through MOHAP’s drug registration directorate; each product requires a full dossier including clinical data, manufacturing site information, pharmacopoeia references, and stability studies; fees run AED 5,000–25,000 per product; timelines range from 6 to 24 months. Medical devices require MOHAP establishment approval for the company plus separate ESMA product registration for each device; devices are categorised as Class I (low risk, self-declaration, 1–3 months, AED 3,000–5,000), Class II (medium risk, 3–9 months, AED 5,000–10,000), or Class III (high risk and implantable, 12–18 months, AED 10,000–15,000). A company that imports both pharmaceuticals and medical devices must maintain separate active registrations under both the MOHAP drug registration framework and the ESMA medical device framework simultaneously.

What are the total product registration costs for a pharmaceutical company entering the UAE with multiple products?

Product registration is charged on a per-product, per-application basis by MOHAP, with fees ranging from AED 5,000 to AED 25,000 per product. A company entering with five products faces registration fees of AED 25,000–125,000 before a single commercial transaction. For a portfolio of 20 products, registration fees alone reach AED 100,000–500,000 — and that excludes dossier preparation costs, regulatory consultancy fees, local agent costs, translation requirements, and any laboratory testing that specific drug categories require. Because each product registration runs on its own timeline of 6–24 months, companies with large portfolios routinely stagger submissions: the highest-revenue products are registered first, generating cash flow that funds subsequent registration rounds for the broader portfolio.